Pharsight

Quzyttir is owned by Jdp.

Quzyttir contains Cetirizine Hydrochloride.

Quzyttir has a total of 5 drug patents out of which 0 drug patents have expired.

Quzyttir was authorised for market use on 04 October, 2019.

Quzyttir is available in solution;intravenous dosage forms.

Quzyttir can be used as method of treatment in patients with concomitant angioedema, method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria, treatment of acute urticaria.

The generics of Quzyttir are possible to be released after 28 February, 2030.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180090	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (6 years from now)
US8513259	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (6 years from now)
US9119771	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (6 years from now)
US8314083	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (6 years from now)
US8263581	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (6 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Oct 4, 2022

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 October, 2019

Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...

Dosage: SOLUTION;INTRAVENOUS